G1 Therapeutics Balance Sheet Health
Financial Health criteria checks 4/6
G1 Therapeutics has a total shareholder equity of $35.4M and total debt of $51.6M, which brings its debt-to-equity ratio to 145.7%. Its total assets and total liabilities are $121.5M and $86.2M respectively.
Key information
145.7%
Debt to equity ratio
US$51.56m
Debt
| Interest coverage ratio | n/a |
| Cash | US$82.16m |
| Equity | US$35.39m |
| Total liabilities | US$86.15m |
| Total assets | US$121.54m |
Recent financial health updates
Does G1 Therapeutics (NASDAQ:GTHX) Have A Healthy Balance Sheet?
Feb 06
Health Check: How Prudently Does G1 Therapeutics (NASDAQ:GTHX) Use Debt?
Apr 19G1 Therapeutics (NASDAQ:GTHX) Has Debt But No Earnings; Should You Worry?
Dec 07G1 Therapeutics (NASDAQ:GTHX) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Sep 03Recent updates
Why G1 Therapeutics Is A Speculative 'Buy' In The Oncology Biotech Landscape
Mar 22Why Investors Shouldn't Be Surprised By G1 Therapeutics, Inc.'s (NASDAQ:GTHX) 44% Share Price Plunge
Feb 27Does G1 Therapeutics (NASDAQ:GTHX) Have A Healthy Balance Sheet?
Feb 06G1 Therapeutics, Inc. (NASDAQ:GTHX) Stock Catapults 61% Though Its Price And Business Still Lag The Industry
Jan 04Little Excitement Around G1 Therapeutics, Inc.'s (NASDAQ:GTHX) Revenues
Jun 08New Forecasts: Here's What Analysts Think The Future Holds For G1 Therapeutics, Inc. (NASDAQ:GTHX)
May 08The G1 Therapeutics, Inc. (NASDAQ:GTHX) Analysts Have Been Trimming Their Sales Forecasts
Nov 04G1 Therapeutics: Catalysts Stacking
Oct 20G1 Therapeutics: Building A Franchise
Sep 29Analysts Just Published A Bright New Outlook For G1 Therapeutics, Inc.'s (NASDAQ:GTHX)
Aug 04G1 Therapeutics Q2 2022 Earnings Preview
Aug 02G1 Therapeutics: Take Advantage Of The November Data
Jul 22G1 Therapeutics granted regulatory nod for cancer therapy in China
Jul 13G1 Therapeutics: Needs To Expand Labels And Commercialize Better
Apr 27Health Check: How Prudently Does G1 Therapeutics (NASDAQ:GTHX) Use Debt?
Apr 19G1 Therapeutics: Biotech With FDA Approved Drug Plus Additional Potential
Feb 08G1 Therapeutics (NASDAQ:GTHX) Has Debt But No Earnings; Should You Worry?
Dec 07G1 Therapeutics: Market May Be Terribly Underestimating This Company
Nov 20G1 Therapeutics (NASDAQ:GTHX) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Sep 03G1 Therapeutics: Poised To Deliver A Blockbuster
Aug 28G1 Therapeutics: Pullback Presents Opportunity
Aug 16News Flash: Analysts Just Made A Captivating Upgrade To Their G1 Therapeutics, Inc. (NASDAQ:GTHX) Forecasts
Aug 08Financial Position Analysis
Short Term Liabilities: GTHX's short term assets ($114.9M) exceed its short term liabilities ($29.7M).
Long Term Liabilities: GTHX's short term assets ($114.9M) exceed its long term liabilities ($56.4M).
Debt to Equity History and Analysis
Debt Level: GTHX has more cash than its total debt.
Reducing Debt: GTHX's debt to equity ratio has increased from 0% to 145.7% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: GTHX has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if GTHX has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.